Sekisui Kagaku Kogyo Kabushiki Kaisha

Nippon Oil Fats Co., Ltd.

Sanwa Kagaku Kenkyusho Co., Ltd.

Hiroko Tsukahara

Masayasu Kurono

Makoto Sato

Tsutomu Ishida

Mutsumi Fukuda

Masato Azuma

Takashi Nakagawa

Kazushi Tokita

Hiroshi Kuroda

Mitsuji Nakano

A percutaneous-administration-type pharmaceutical preparation of nitroglycerin is provided. The preparation comprises a backing that is impervious to medicines, and a pressure-sensitive adhesive layer that is placed on one surface of said backing, wherein said pressure-sensitive adhesive layer contains an alkyl (meth)acrylate (co)polymer in the concentration of 35-85% by weight, nitroglycerin in the concentration of 10-30% by weight, and a silicic acid anhydride in the concentration of 5-20% by weight, said (co)polymer contains as major (co)polymer components alkyl (meth)acrylates with alkyl groups having 6 or more carbon atoms, which alkyl (meth)acrylates include 2-ethylhexyl methacrylate in the concentration of 40-100% by weight based on the total weight of said alkyl (meth)acrylates. The preparation makes it possible for nitroglycerin to be absorbed percutaneously at a controlled rate for a long period of time. Also, even a compact preparation can supply a sufficient amount of nitroglycerin. Moreover, the preparation can be manufactured at low cost without any complicated process.

Percutaneous-administration-type pharmaceutical preparation of

A percutaneous pharmaceutical preparation in tape form is provided. The preparation comprises a flexible backing, which is not permeable to an active ingredient, and an adhesive layer formed on the flexible backing, the adhesive layer comprising an adhesive base material and an active ingredient compatible with the adhesive base material, wherein the adhesive base material consists essentially of a copolymer containing 2-ethylhexyl acrylate in a concentration of 45 to 80 mol % and N-vinyl-2-pyrrolidone in a concentration of 20 to 55 mol %, and the active ingredient is estradiol and/or the esters thereof which are contained in a concentration of 6 to 25% by weight of the total amount of the adhesive base material and the active ingredient.

Percutaneous pharmaceutical preparation

Growing community of inventors

Takatsuki, Japan

Hiroko Tsukahara